Next Article in Journal
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
Next Article in Special Issue
Oncolytic Viruses for Canine Cancer Treatment
Previous Article in Journal
The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Cancers 2018, 10(8), 276;

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression

Department of Immunology and Pathology, Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria 3004, Australia
Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China
Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia
Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria 3168, Australia
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083, Australia
Authors to whom correspondence should be addressed.
Received: 29 June 2018 / Revised: 13 August 2018 / Accepted: 14 August 2018 / Published: 20 August 2018
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Full-Text   |   PDF [2051 KB, uploaded 20 August 2018]   |  


The cancer testis antigen sperm protein 17 (Sp17) is a promising antigenic target in epithelial ovarian cancer (EOC) vaccine development. However, its role in ovarian cancer is unclear. We isolated and expanded Sp17+ and Sp17 clones from the murine EOC cell line ID8, and compared their in-vitro cell growth characteristics and in-vivo tumorigenicity. We also examined the potential co-expression of molecules that may influence cancer cell survival and interaction with immune cells. These include stimulatory and immunosuppressive molecules, such as major histocompatibility class I molecules (MHC I), MHC II, cytotoxic T lymphocyte associated antigen-4 (CTLA-4), CD73, CD39, tumor necrosis factor receptor II (TNFRII), signal transducer and activator of transcription 3 (STAT3) and programmed death-ligand 1 (PD-L1). Whilst the presence of Sp17 was not correlated with the ID8 cell proliferation/growth capacity in vitro, it was critical to enable progressive tumor formation in vivo. Flow cytometry revealed that Sp17+ ID8 cells displayed higher expression of both STAT3 and PD-L1, whilst MHC II expression was lower. Moreover, Sp17high (PD-L1+MHCII) cell populations showed significantly enhanced resistance to Paclitaxel-induced cell death in vitro compared to Sp17low (PD-L1MHCII+) cells, which was associated in turn with increased STAT3 expression. Together, the data support Sp17 as a factor associated with in-vivo tumor progression and chemo-resistance, validating it as a suitable target for vaccine development. View Full-Text
Keywords: sperm protein 17 (Sp17); ID8; PD-L1; STAT3; MHC II; Paclitaxel; tumor resistant; immune evasion sperm protein 17 (Sp17); ID8; PD-L1; STAT3; MHC II; Paclitaxel; tumor resistant; immune evasion

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Gao, Q.; Xiang, S.D.; Wilson, K.; Madondo, M.; Stephens, A.N.; Plebanski, M. Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression. Cancers 2018, 10, 276.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top